Coronavirus (COVID-19)
Learn more
May 09, 2017
Sponsor: National Cancer Institute (NCI)
Number: RTOG-1306
Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II trial (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety) studies how well erlotinib hydrochloride or crizotinib with chemoradiation therapy works in treating patients with stage III non-small cell lung cancer. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Chemotherapy drugs such as Cisplatin, Etoposide, Paclitaxel, and Carboplatin, work in different ways to stop the growth of tumor cells. The chemotherapydrugs stop the growth by either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving Erlotinib Hydrochloride is more effective than Crizotinib with chemo-radiation therapy in treating patients with non-small cell lung cancer.
Who’s eligible:
Available at: The Hospital of Central Connecticut, Backus Hospital, and Hartford Hospital.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209